Boundless Bio $100M IPO to Advance Novel Cancer Therapies
Boundless Bio, a biotech company pioneering a new approach to treating cancer, made its public debut on the Nasdaq stock exchange today in a $100 million initial public offering.
0
4 min read
Noble Capital Markets Research Morning Call
Today’s Noble Capital Markets equity research reports, available with free...
65 min read
Big Pharma Goes Bio-Prospecting: Why Major Drug Makers Are Buying Innovative Biotech Startups
3 min read
Alamos Gold’s Acquisition of Argonaut Gold Points to Renewed Anticipation Mining Sector
We’ve updated the entire site to bring you faster navigation and increased content at every level. Channelchek is now North America’s leading platform for access to regulated and independent company sponsored equity research.